Stockscreener 앱 받기
10.76
0.92%
-0.10
시간 외 거래:
10.95
0.19
+1.77%
전일 마감가:
$10.86
열려 있는:
$10.88
하루 거래량:
1.23M
Relative Volume:
0.67
시가총액:
$957.22M
수익:
$71.64M
순이익/손실:
$-294.57M
주가수익비율:
-3.2139
EPS:
-3.348
순현금흐름:
$-84.46M
1주 성능:
-8.27%
1개월 성능:
-20.82%
6개월 성능:
+25.85%
1년 성능:
+28.71%
1일 변동 폭
$10.75
$10.96
1주일 범위
$10.66
$12.00
52주 변동 폭
$7.3575
$13.90
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
10.76 | 957.22M | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Lake Street | Buy |
| 2025-09-04 | 개시 | Guggenheim | Neutral |
| 2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-08-11 | 개시 | BofA Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-05-17 | 개시 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 개시 | Jefferies | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-11-09 | 개시 | Piper Jaffray | Overweight |
| 2018-08-01 | 개시 | H.C. Wainwright | Buy |
| 2016-10-13 | 재개 | Leerink Partners | Outperform |
| 2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-30 | 개시 | Oppenheimer | Outperform |
| 2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Kura Oncology CSO Francis Burrows Executes Stock Option and Sells Shares in September 2026 - Kalkine Media
After exercising options, Kura Oncology (KURA) science chief sold 20,726 shares to cover estimated payroll taxes. - Stock Titan
Form 144 KURA ONCOLOGY For: 25 September By Investing.com - Investing.com South Africa
Shares from a stock option exercise are proposed for sale by a Kura Oncology (KURA) officer, valued at $224,514. - Stock Titan
Why (KURA) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Kura Oncology stock holds at USD 11.73 as Caspian launches - AD HOC NEWS
Kura Oncology, Inc. (KURA) Stock Analysis: A Biotech Innovator with a 173% Potential Upside - DirectorsTalk Interviews
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura Oncology to present at three investor conferences in September - scanx.trade
Kura Oncology Q2 2026 Earnings Call Transcript - Benzinga
Kura Oncology at Morgan Stanley conference: early sales, bigger bets By Investing.com - Investing.com Nigeria
Kura Oncology at Morgan Stanley conference: early sales, bigger bets - Investing.com
Kura Oncology (KURA) awards CFO 450,000 stock options - Stock Titan
Kura Oncology (KURA) CFO files initial ownership report with no trades - Stock Titan
Kura Oncology Maintains 49.2% Stake in Caspian Therapeutics Following $50M Series A Funding - Kalkine Media
symbol__ Stock Quote Price and Forecast - CNN
Kura Spins Out Caspian With $50m To Test Menin Inhibition In Diabetes - insights.citeline.com
Kura assets flow to Caspian for cardiometabolic indications - BioWorld News
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary - AOL.com
Kura Oncology Raises $50M for Cardiometabolic Subsidiary Caspian - minichart.com.sg
KURA Oncology Launches Caspian Therapeutics, Shifting Focus Whil - GuruFocus
Kura Oncology at cantor conference: rapid launch, wider ambitions - Investing.com India
Kura Oncology at cantor conference: rapid launch, wider ambitions By Investing.com - Investing.com Canada
Kura Oncology, Inc. Enters into Contribution and License and Intercompany Services Agreement with Caspian Therapeutics, Inc - marketscreener.com
Kura Oncology Launches Caspian Therapeutics With $50 Million Funding - marketscreener.com
Kura Oncology Appoints Jennifer Fulk as New CFO - The Globe and Mail
Kura Oncology Establishes Caspian Partnership for Cardiometabolic Focus - TipRanks
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes - The Manila Times
Eli Lilly is among investors in a new diabetes company with $50 million - Stock Titan
Kura Oncology spins out diabetes pipeline with $50M and Lilly’s help - Endpoints News
KURA: Strong commercial momentum and advancing late-stage pipeline position for major growth - TradingView
KURA: Strong commercial momentum and advancing late-stage pipeline position for major growth by 2028 - TradingView
Kura Oncology at Wells Fargo conference: launch gains and pipeline breadth - investing.com
Kura Oncology Names Jennifer Fulk as Chief Financial Officer Effective September 8, 2026 - Kalkine Media
Kura Oncology Names Jennifer Fulk Chief Financial Officer - Minichart
Kura Oncology, Inc. Announces Chief Financial Officer Changes, Effective September 8, 2026 - marketscreener.com
Kura Oncology Names Jennifer Fulk Finance Chief - marketscreener.com
Jennifer Fulk named CFO of Kura Oncology, replacing Troy E. Wilson and Thomas Doyle - TradingView
New Kura Oncology (KURA) CFO gets 450,000 options and up to 18 months of severance pay - Stock Titan
A former Eli Lilly executive takes Kura's top finance job - Stock Titan
Four new hires get options to buy 48,450 Kura shares - Stock Titan
Price-Driven Insight from (KURA) for Rule-Based Strategy - Stock Traders Daily
Kura Oncology (KURA) Stock Looks Fully Priced After Its 56% Run - finance.yahoo.com
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know - TradingView
Kura Oncology to Participate in Three Investor Conferences in September - GlobeNewswire
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Cancer Biotech Kura Oncology Rallies to New High After CEO’s Stock Purchase - Barron's
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last? - qz.com
Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects - Seeking Alpha
Kura Oncology Shares Rise After CEO Purchases 100,000 Shares - marketscreener.com
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):